5-甲基胞嘧啶RNA甲基化在非腫瘤性腎臟疾病中的研究進(jìn)展

打開文本圖片集

中圖分類號(hào)：R692 文獻(xiàn)標(biāo)識(shí)碼：A 文章編號(hào)：1000-503X（2025）01-0086-09

DOI：10.3881/j.issn.1000-503X.16053

Current Progress of 5-Methylcytosine RNA Methylation in Non-Neoplastic Kidney Diseases

ZHANG Chen， ZHAO Zixia，WU Si，LUAN Junjun，ZHOU Hua

Department ofNephrology，Shengjing Hospital of China Medical University，Shenyang 11OooO，China

Corresponding author：ZHOU Hua Tel：O24-96615-25211，E-mail：huazhou_cmu@163.com

ABSTRACT：RNA methylation is a key process in the epigenetic regulation of post-transcriptional gene expression.5-Methylcytosine （ m5C ）is a type of RNA methylation， commonly existing in eukaryotic mRNA and non-coding RNAs.It mainly regulates transfer RNA stability，ribosomal RNA assembly，and mRNA translation， stability，and translation.RNA methylation isdynamicallreversibleandregulated bymethyltransferase，demethylase，and methylation recognition protein.It has been confirmed that aberrant m5C RNA methylation is involved inthe pathogenesis of non-neoplastic kidney diseases.Thisarticle summarizes the current progress of （204 m5C RNA methylation associated with non- neoplastic acute and chronic kidney diseases，aiming to provide potential targets for the diagnosis and treatment of such diseases.

Key Words：epigenetics；RNA methylation；RNA；5-methylcytosine；kidney diseases

ActaAcadMedSin，2025，47（1） ：86-94

非腫瘤性腎臟疾病按起病的急緩可分為急性腎損傷（acutekidneyinjury，AKI）和慢性腎臟病（chronickidneydisease，CKD）。（剩余20251字）